Lake Street analyst Brooks O’Neil downgraded Cardiovascular Systems (CSII) to Sell from Buy with a price target of $20, down from $25, after Abbott (ABT) announced a deal to acquire the company for $20 per share in cash. While stating "it is always possible another potential acquirer might offer a higher price," the firm does not think this is likely and suggests investors sell Cardiovascular Systems as it approaches the deal price given the view that "there is always some risk the transaction might not close."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CSII:
- Cardiovascular Systems jumps 43% after announcing it is being acquired by Abbott
- Cardiovascular Systems reports Q2 EPS (20c), consensus (15c)
- Abbott to acquire Cardiovascular Systems for $20 per share, or $890M
- Cardiovascular Systems enrolls first patient in Japan for Kaizen study
- Cardiovascular Systems announces 510k submission of Innova’s thrombectomy system